Assessment of Mast Cell Mediators in Pediatric Patients with Clinical Symptoms of Autonomic Dysfunction


About this study

The purpose of this study is to determine if there are increases in mast cell mediators in subjects with autonomic dysfunction.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Pediatric patients (aged 8-18 years) with chronic symptoms (>3 months) symptoms of  lightheadedness, syncope, headache, fatigue, weakness, sweating, nausea and heart palpitations, flushing, generalized puritis or dermatographism. 
  • Consent obtained from a responsible guardian AND from subjects 8-17 years of age OR consent obtained from subjects 18 years of age.  

Exclusion Criteria:

  • Previous diagnosis of a primary mast cell disorder (Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome) or secondary mast cell activation disorder (IgE-mediated allergies).
  • Concomitant therapy with anticholinergic, alpha-adrenergic antagonists, beta-adrenergic antagonists or other medications which could interfere with autonomic testing.  Patients may participate if the potentially interfering medication is held for five half-lives prior to the study

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Amie Jones, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer